PT-141 animal studies vs human evidence: what translates

Last updated 2026-07-24

What did early animal studies show about PT-141?

Early PT-141 research used rodent models to test whether a melanocortin receptor agonist could trigger sexual behavior centrally, bypassing the vascular effects of drugs like sildenafil. The hypothesis was simple: stimulate the melanocortin system in the brain and you should see an increase in sexual motivation. Researchers observed that PT-141 induced lordosis (the receptive posture in female rodents) and increased copulation attempts in male rats ^[1]. The peptide was given intranasally or subcutaneously, and behavior was scored within hours. The effect was dose-dependent, meaning higher doses produced stronger responses up to a ceiling. Importantly, these behavioral changes happened without changes in peripheral blood flow or genital engorgement, confirming the central mechanism ^[2]. Animal models are clean systems. You control diet, environment, and estrous cycle. You can rule out psychosocial confounders that mess up human trials. If PT-141 made a rat seek out a partner more often, the melanocortin pathway was doing something real. But animal studies don't capture subjective desire, relationship context, or the distress that defines hypoactive sexual desire disorder in humans. A rat either mates or it doesn't. A human can feel desire, not act on it, and still be distressed by the lack. That gap is the entire reason we need human trials.

How does the mechanism work centrally in both species?

PT-141 is a cyclic heptapeptide that binds to melanocortin receptors (primarily MC3R and MC4R) in the hypothalamus and limbic system ^[3]. The melanocortin system modulates appetite, energy expenditure, and sexual behavior. Activation of MC4R in the paraventricular nucleus has been linked to increased sexual arousal in both rodents and primates ^[4]. When PT-141 binds these receptors, it shifts the balance of excitatory and inhibitory pathways that regulate sexual motivation. The drug doesn't trigger genital vasodilation or increase testosterone. It changes how the brain prioritizes sexual cues. That's why it's called a centrally acting agent ^[5]. In humans, the same receptors exist in the same brain regions. fMRI studies in women treated with bremelanotide have shown altered activity in the insula and anterior cingulate cortex during sexual imagery, though these studies are small and don't yet map cleanly onto subjective desire ^[6]. The receptor biology translates; the behavioral output is noisier. One key difference: humans have a much larger prefrontal cortex and more complex inhibitory control. A rat's sexual behavior is tightly coupled to hormonal and receptor-level signals. A human can override arousal for a hundred reasons (fatigue, stress, relationship conflict, self-consciousness). PT-141 can push the accelerator, but it doesn't remove the brakes ^[7].

What did phase 3 human trials find?

Two randomized, double-blind, placebo-controlled trials (RECONNECT-1 and RECONNECT-2) enrolled 1,247 premenopausal women with hypoactive sexual desire disorder ^[8]. Women self-injected 1.75 mg bremelanotide subcutaneously as needed, up to one dose per 24 hours and no more than eight doses per month, for 24 weeks. The co-primary endpoints were change from baseline in the number of satisfying sexual events (SSEs) and change in desire score on the Female Sexual Function Index (FSFI). Women in the bremelanotide arm had about 0.5 more SSEs per month than placebo (from roughly 2.5 to 3.0 versus 2.5 to 2.7) ^[8]. The FSFI desire domain increased by roughly 0.3 points more than placebo on a 6-point scale. Both differences were statistically significant (p < 0.001). Distress, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), decreased more in the bremelanotide group (around 6 points versus 4 points placebo). The effect size here was about 0.3 standard deviations, which is small but clinically meaningful for some women ^[8]. About 25% of bremelanotide-treated women reported nausea, and 13% had flushing ^[9]. Most nausea was mild to moderate and occurred within two hours of injection. Discontinuation due to adverse events was around 8% for bremelanotide versus 1% for placebo ^[9]. These trials were well-designed. They excluded women on antidepressants that impair libido, required a stable relationship, and used a run-in period to screen out placebo responders. The effect was real but modest. The number needed to treat (NNT) for one additional satisfying sexual event per month is debated, but reanalysis puts it around 8 to 10 ^[10].

How do effect sizes compare between animals and humans?

Animal studies report large effect sizes because the behavioral endpoints are binary and the conditions are controlled. A treated rat might show a 50% to 100% increase in copulation attempts over saline controls in a 30-minute observation ^[1]. The signal is loud. In humans, the increase in desire-related outcomes was smaller. One additional satisfying sexual event every two months, or a 0.3-point shift on a 6-point scale, is meaningful to some women but underwhelming on paper. Critics have noted that the clinical significance threshold for FSFI desire is about 0.5 points ^[11], and the trial barely crossed that. Why the gap? Humans self-report subjective desire, which is influenced by mood, relationship quality, and context. The FSFI asks about desire "over the past four weeks," a noisy window. Animal copulation is observable and immediate. The trial design also allowed rescue doses (women could use the drug only when anticipating activity), which introduced variability. Some women used one dose per month; others used eight ^[12]. Responder analyses show that about 40% of women in the bremelanotide group had a clinically meaningful improvement in desire (defined as ≥0.6 points on FSFI desire) versus 30% in placebo ^[13]. That 10 percentage-point difference is the signal animal studies would predict, just diluted by the heterogeneity of human sexual dysfunction. Another factor: animal studies typically use healthy, sexually mature subjects. The human trials enrolled women with HSDD, a condition often comorbid with depression, stress, and relationship problems. A drug that works well in a clean system may show smaller effects in a complex one.

What side effects showed up in humans but not animals?

Nausea was the standout. About 25% of women in phase 3 trials reported nausea, and it was the most common reason for discontinuation ^[9]. Nausea typically started within 30 minutes of injection, peaked around two hours, and resolved by four hours. Pretreatment with an antiemetic (like ondansetron) wasn't studied in the registration trials, but some clinicians now recommend it off-label ^[14]. Flushing (facial redness and warmth) occurred in about 13% of women ^[9]. It's likely a central vasomotor effect mediated by melanocortin receptors, not peripheral vasodilation. The flushing was transient but noticeable enough to make some women avoid public situations after dosing. Animal studies rarely report nausea. Rodents can't vomit (they lack the emetic reflex), so nausea is hard to detect in preclinical studies. Behavioral measures like pica (eating non-nutritive substances) can suggest nausea, but it's not routinely scored in PT-141 studies ^[15]. Flushing is also hard to observe in furred animals. Hypertension was a concern in early intranasal trials, where transient spikes in blood pressure led to a clinical hold ^[2]. Subcutaneous dosing at 1.75 mg produced much smaller increases (average 2 to 3 mmHg systolic), not clinically significant in healthy women ^[9]. The FDA still advises caution in women with uncontrolled hypertension. Headache and injection-site reactions (redness, swelling) were also more common than placebo but rarely led to discontinuation ^[9]. No animal model reliably predicts these tolerability issues, which is why phase 1 and 2 dose-finding trials are essential.

Did animal studies predict the human dose?

Not directly. Rodent studies used doses that translate to much higher human-equivalent exposures when adjusted for body surface area. A typical rat study might give 1 to 10 mg/kg subcutaneously ^[1]. A 70 kg human at 1 mg/kg would need 70 mg, but the approved human dose is 1.75 mg total. The disconnect comes from pharmacokinetics and receptor density. Peptides like PT-141 have poor oral bioavailability and short half-lives (around 2.7 hours in humans) ^[16]. The drug needs to cross the blood-brain barrier, and that efficiency varies by species. Rodents have faster metabolism and different receptor distributions, so direct dose translation is unreliable. Phase 1 and 2 trials in humans tested doses from 0.25 mg to 2.0 mg. The 1.75 mg dose balanced efficacy and tolerability, with a response rate (by multiple endpoints) around 25% to 30% over placebo ^[17]. Higher doses (2.0 mg) didn't improve efficacy much but increased nausea sharply ^[17]. Animal studies set the mechanistic foundation ("melanocortin agonism can trigger sexual behavior") but didn't predict the human therapeutic window. That required human dose-ranging trials. This is typical for centrally acting drugs, where the dose-response curve is steep and narrow.

Which populations were studied in animals but not humans?

Most animal work used young, healthy, sexually mature subjects. The human trials focused exclusively on premenopausal women (ages 18 to menopause) with a diagnosis of hypoactive sexual desire disorder ^[8]. Women with significant medical or psychiatric comorbidities were excluded. Postmenopausal women were not included in the phase 3 trials, even though low desire is common in that group. The FDA approval is limited to premenopausal women ^[18]. Some clinicians prescribe off-label for postmenopausal patients, but the evidence base is thin. A small phase 2 study in postmenopausal women showed modest benefit, but it didn't reach the efficacy threshold needed for regulatory approval ^[19]. Men were studied in early trials (PT-141 was initially developed for erectile dysfunction), but efficacy was inconsistent ^[20]. The drug didn't improve erections reliably, and side effects (nausea, flushing) were worse than with PDE5 inhibitors. Animal studies in male rats showed pro-sexual effects, but human translation failed. The reasons aren't fully clear, though differences in melanocortin receptor distribution and psychogenic erectile function may contribute. Women on SSRIs (a common cause of low libido) were excluded from the registration trials. A subgroup analysis later suggested bremelanotide might work in this population, but the data are preliminary ^[21]. If you're deciding between PT-141 and blood work before starting, know that most trial participants were medically healthy. Animal models also can't capture relationship distress, a core diagnostic criterion for HSDD. A rat doesn't need a stable partnership or relationship satisfaction to mate. Human trials required women to be in a stable relationship for at least six months, which limits generalizability.

How did animal studies inform the central mechanism claim?

The key insight from animals: PT-141's effects are blocked by melanocortin receptor antagonists and don't depend on peripheral blood flow. In rodent studies, co-administration of a selective MC4R antagonist (like HS024) abolished the pro-sexual effects of PT-141, confirming the receptor target ^[4]. Genital blood flow was measured in some animal studies using laser Doppler flowmetry. PT-141 didn't increase vaginal or clitoral perfusion in rats, unlike drugs that act on the nitric oxide pathway ^[2]. The same was true in human studies: bremelanotide doesn't alter genital engorgement measured by vaginal photoplethysmography ^[5]. This mechanistic clarity is the reason bremelanotide is called a centrally acting libido drug. It's not a vasodilator. It's not hormonal (doesn't increase estrogen or testosterone). It works in the brain, specifically in hypothalamic and limbic circuits that gate sexual motivation ^[5]. Animal studies also showed that PT-141's effects are context-dependent. A treated rat placed alone in a cage doesn't show sexual behavior; you need a receptive partner present. The drug enhances motivation to seek and respond to sexual cues, but it doesn't create desire out of nothing ^[1]. Human trials captured this indirectly: bremelanotide worked best on measures of desire in response to sexual stimuli (the desire domain of FSFI), less so on spontaneous desire. The neurobiology review in CNS Spectrums synthesizes this: "Bremelanotide's action on MC3R and MC4R in the hypothalamus and amygdala modulates neural circuits that integrate sensory input, emotional valence, and autonomic arousal, culminating in the subjective experience of desire" ^[6]. That's a fancy way of saying the drug tweaks the system that decides whether a sexual cue is interesting.

What did reanalysis of the phase 3 data reveal?

Several independent reanalyses have questioned the clinical significance of bremelanotide's effects. A 2021 paper in the Journal of Sex Research recalculated the number needed to treat (NNT) using responder definitions and found an NNT of 8 to 12 for a meaningful increase in satisfying sexual events ^[10]. That means eight women need to use the drug for one to see a benefit beyond placebo. The same reanalysis noted that the absolute increase in SSEs was less than one event per month, and the placebo response was substantial (around 50% of women reported some improvement) ^[10]. The authors concluded that bremelanotide "has a statistically significant but small effect" and that "the clinical utility for most women is limited." A 2024 paper in the same journal amplified this critique, arguing that the trials used composite endpoints (combining desire, arousal, and distress) that inflate the appearance of benefit ^[11]. The FDA approval relied on co-primary endpoints (SSEs and FSFI desire), both of which showed small but significant changes. Critics argue the distress reduction (FSDS-DAO) is the only patient-centered outcome that matters, and even there the effect size was about 0.3 ^[11]. The Drug and Therapeutics Bulletin (UK) published a skeptical review in 2021, stating that "the size of the treatment effect is small and of uncertain clinical relevance" and recommending that bremelanotide "should not be used routinely" ^[22]. The review noted the high cost (around $1,000 per month in the U.S.) and the lack of long-term safety data beyond 24 weeks. On the other hand, responder analyses (women who improved by a clinically meaningful threshold) showed about 10% more responders on bremelanotide than placebo ^[13]. If you're in that 10%, the drug works. If you're in the 90%, you get placebo-level benefit or side effects. Animal studies can't predict which humans will respond.

How do safety profiles differ between animal toxicology and human trials?

Animal toxicology studies (required for FDA approval) test higher doses over longer durations than human therapeutic use. Rats and dogs were given PT-141 at doses up to 50 mg/kg for 13 to 26 weeks ^[16]. The main findings were transient increases in blood pressure, darkening of skin and fur (a known effect of melanocortin agonists), and mild gastrointestinal disturbances. No carcinogenicity signal was seen in two-year rodent studies ^[16]. Human trials tracked adverse events systematically. The integrated safety analysis across all phase 2 and 3 studies (over 1,200 women) found that nausea, flushing, headache, and injection-site reactions were the most common events ^[9]. Serious adverse events were rare (about 1% in both bremelanotide and placebo groups) and not clearly drug-related ^[9]. One concern from animal studies was cardiovascular risk. Early intranasal formulations caused transient hypertension in some humans, leading to a clinical hold and a switch to subcutaneous dosing ^[2]. Subcutaneous bremelanotide at 1.75 mg produces small, transient increases in blood pressure (2 to 3 mmHg systolic) that peak around one hour and resolve by four hours ^[9]. This isn't clinically significant in normotensive women but led to a contraindication in women with uncontrolled hypertension or known cardiovascular disease ^[18]. No long-term (>24 weeks) controlled safety data exist. The drug's approval was based on 24-week trials. Observational data and case reports are accumulating, but we don't know if chronic melanocortin stimulation has late toxicities. Animal tox studies don't predict chronic low-dose effects well, because they use high doses to amplify any signal. If you're comparing PT-141 in women to other treatments, remember that the safety profile is based on relatively short exposure windows in a selected population.

What evidence gaps remain between animal and human data?

Several questions can't be answered by either animal studies or the existing human trials. First, does bremelanotide work in postmenopausal women? Animal models of menopause (ovariectomized rodents) show that PT-141 retains some pro-sexual effects ^[1], but the phase 3 trials excluded this group. A dedicated postmenopausal trial would need to run. Second, what happens with chronic use over years? The trials lasted 24 weeks. Women who benefit may use the drug for much longer. Does tolerance develop? Do melanocortin receptors downregulate? Animal models haven't tested this, because rodent lifespans are short and chronic dosing studies are expensive. Third, does bremelanotide work for HSDD caused by SSRIs or other medications? A post hoc subgroup analysis suggested possible benefit ^[21], but the trial wasn't powered to answer this. Animal studies can't model SSRI-induced sexual dysfunction well, because rodent serotonin systems differ from humans. Fourth, what's the influence of genetic variation in melanocortin receptors? Some women have polymorphisms in MC4R or MC3R that might predict response ^[23]. No genotype-stratified trials have been done. Animal studies use inbred strains, so genetic variability is minimal. Fifth, how does bremelanotide compare head-to-head with flibanserin (the other FDA-approved HSDD drug)? No direct comparison trial exists. Both drugs have modest effect sizes, different mechanisms, and different side effect profiles. An animal model can't answer which is better for a given patient ^[22]. If you're looking at best place to buy PT-141 or PT-141 peptide therapy near me, know that the evidence base is incomplete. The drug works centrally, the animal studies predicted that, but the real-world benefit is modest and individual.

Frequently asked questions

Do animal studies predict whether PT-141 will work for me?

No. Animal studies show the drug can activate melanocortin receptors and trigger sexual behavior, but they can't predict individual human response. About 40% of women in phase 3 trials had a meaningful improvement, versus 30% on placebo. Factors like relationship quality, stress, and comorbid conditions (not modeled in animals) affect outcomes. The only way to know is a trial under medical supervision.

Why did PT-141 work better in rats than in women?

Effect sizes look larger in animals because the behavioral endpoints are simpler (copulation attempts, lordosis) and the conditions are controlled. Human desire is subjective, context-dependent, and measured over weeks. The mechanistic effect (melanocortin activation) translates, but the behavioral output is noisier in humans. Rats don't have relationship distress or self-consciousness.

Did animal studies predict the nausea?

No. Rodents can't vomit, so nausea is hard to detect in preclinical studies. Human phase 1 trials were the first signal that nausea was a dose-limiting side effect. About 25% of women in phase 3 trials reported nausea, most mild to moderate and resolving within two to four hours. Pretreatment with an antiemetic is sometimes used off-label.

Can PT-141 be tested in postmenopausal women based on animal data?

Animal studies in ovariectomized rats (a menopause model) suggest PT-141 retains some pro-sexual effects, but human trials excluded postmenopausal women. A small phase 2 study showed modest benefit, not enough for FDA approval. Off-label use happens, but the evidence is thin. A dedicated postmenopausal trial is needed.

How did researchers pick the 1.75 mg dose?

Phase 2 dose-ranging trials in humans tested 0.25 mg to 2.0 mg subcutaneous doses. The 1.75 mg dose balanced efficacy (response rate about 25% to 30% over placebo) and tolerability (nausea ~25%). Higher doses didn't improve efficacy much but sharply increased nausea. Animal dosing (1 to 10 mg/kg in rats) doesn't translate directly due to pharmacokinetic and receptor differences.

Do animal studies explain why PT-141 doesn't cause genital engorgement?

Yes. Rodent studies showed PT-141 doesn't increase vaginal blood flow (measured by laser Doppler). The drug acts centrally on melanocortin receptors in the brain, not peripherally on vascular smooth muscle. This was confirmed in human studies using vaginal photoplethysmography. PT-141 is a libido drug, not a vasodilator like sildenafil.

Were men excluded from PT-141 trials based on animal data?

No. Men were included in early trials because animal studies showed pro-sexual effects in male rats. But human trials found inconsistent efficacy for erectile dysfunction and worse side effects than PDE5 inhibitors. Development shifted to women with HSDD, where phase 3 trials succeeded. Animal models of male sexual function don't predict human erection reliability well.

How long do PT-141 effects last in animals versus humans?

In rats, behavioral effects (increased copulation, lordosis) peak within one to two hours and last about four to six hours after injection. In humans, desire and arousal changes are measured over weeks (FSFI asks about the past four weeks), so duration per dose is hard to isolate. The drug's half-life is about 2.7 hours in humans, but subjective effects may persist longer.

Can animal studies predict which women will respond to PT-141?

No. Animal studies use genetically uniform strains in controlled conditions. Human responders (about 40% in phase 3 trials) vary by genetics (melanocortin receptor polymorphisms), relationship quality, comorbid depression, and other factors not modeled in rodents. Responder analyses haven't identified strong predictors yet. Individual trial under supervision is the only way to know.

Did animal toxicology studies show any long-term risks?

Two-year rodent studies (at doses up to 50 mg/kg) found no carcinogenicity signal. The main findings were transient hypertension, skin darkening (a melanocortin effect), and mild GI disturbances. Human trials lasted only 24 weeks, so long-term safety in humans (>1 year) is uncertain. Post-market surveillance is ongoing, but no major safety signals have emerged.

Why didn't animal studies predict the blood pressure issue with intranasal PT-141?

Animal BP monitoring is usually done in anesthetized or restrained subjects, which can mask transient spikes. Early human trials with intranasal PT-141 found transient hypertension (systolic increases >20 mmHg in some subjects), leading to a clinical hold. Subcutaneous dosing at 1.75 mg produces much smaller increases (~2 to 3 mmHg), which animal studies did predict at equivalent doses.

Is PT-141 being tested in animals for other conditions?

Yes. Animal studies have explored melanocortin agonists for obesity (MC4R activation reduces appetite), inflammation, and even glioblastoma (a 2024 study found bremelanotide induced cell death in glioblastoma cultures). These are preclinical findings; no human trials for these indications exist yet. The melanocortin system is broad, so off-target effects are possible.

Sources

1. Melanocortins in the treatment of male and female sexual dysfunction, Current Topics in Medicinal Chemistry, 2007: PT-141 induced lordosis and increased copulation attempts in rodents in a dose-dependent manner without altering peripheral blood flow.
2. Bremelanotide: the female Viagra?, Expert Review of Endocrinology & Metabolism, 2006: Intranasal PT-141 caused transient hypertension in early human trials, leading to a clinical hold and switch to subcutaneous dosing; genital blood flow was not increased in animal or human studies.
3. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin, Biomolecules, 2022: PT-141 is a cyclic heptapeptide that binds melanocortin receptors MC3R and MC4R.
4. Targeting the central melanocortin system for the treatment of metabolic disorders, Nature Reviews Endocrinology, 2023: Activation of MC4R in the paraventricular nucleus has been linked to increased sexual arousal in rodents and primates.
5. Bremelanotide for Treatment of Female Hypoactive Sexual Desire, Neurology International, 2022: Bremelanotide is a centrally acting melanocortin receptor agonist that does not trigger genital vasodilation or increase testosterone.
6. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women, CNS Spectrums, 2022: fMRI studies in women treated with bremelanotide showed altered activity in the insula and anterior cingulate cortex during sexual imagery; bremelanotide's action on MC3R and MC4R in the hypothalamus and amygdala modulates neural circuits integrating sensory input, emotional valence, and autonomic arousal.
7. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment, Journal of Midwifery & Women's Health, 2021: Human sexual desire is influenced by prefrontal cortex inhibitory control, relationship quality, stress, and context, factors not present in rodent models.
8. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, Obstetrics and Gynecology, 2019: RECONNECT-1 and RECONNECT-2 trials enrolled 1,247 premenopausal women; bremelanotide increased satisfying sexual events by about 0.5 per month over placebo and FSFI desire domain by roughly 0.3 points; FSDS-DAO distress decreased about 2 points more than placebo; both differences p < 0.001.
9. Safety Profile of Bremelanotide Across the Clinical Development Program, Journal of Women's Health, 2022: About 25% of bremelanotide-treated women reported nausea, 13% flushing, and 8% discontinued due to adverse events versus 1% placebo; transient blood pressure increases averaged 2 to 3 mmHg systolic.
10. Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women, Journal of Sex Research, 2021: Reanalysis found NNT of 8 to 12 for one meaningful increase in satisfying sexual events; absolute increase was less than one event per month; placebo response was about 50%; concluded effect is statistically significant but small.
11. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder, Journal of Sex Research, 2024: Clinical significance threshold for FSFI desire is about 0.5 points; the trial effect was about 0.3 points.
12. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide, Journal of Women's Health, 2022: Trial design allowed rescue dosing; some women used one dose per month, others used eight, introducing variability.
13. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide, The Journal of Sexual Medicine, 2019: About 40% of women in the bremelanotide group had a clinically meaningful improvement in desire (≥0.6 points on FSFI desire) versus 30% in placebo.
14. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder, Expert Opinion on Pharmacotherapy, 2023: Pretreatment with an antiemetic like ondansetron is sometimes used off-label to manage nausea, though not studied in pivotal trials.
15. Pharmacotherapy for Sexual Dysfunction in Women, Current Psychiatry Reports, 2022: Rodents can't vomit, so nausea is hard to detect in preclinical studies; behavioral measures like pica can suggest nausea but are not routinely scored in PT-141 studies.
16. Bremelanotide: First Approval, Drugs, 2019: Bremelanotide has a half-life of about 2.7 hours in humans; animal toxicology studies in rats and dogs at doses up to 50 mg/kg for 13 to 26 weeks found transient hypertension, skin darkening, and mild GI disturbances; no carcinogenicity signal in two-year rodent studies.
17. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder, The Annals of Pharmacotherapy, 2020: Phase 2 trials tested 0.25 mg to 2.0 mg; 1.75 mg balanced efficacy (response rate 25% to 30% over placebo) and tolerability; 2.0 mg didn't improve efficacy much but sharply increased nausea.
18. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder, The Medical Letter on Drugs and Therapeutics, 2019: FDA approval is limited to premenopausal women; contraindication exists for women with uncontrolled hypertension or known cardiovascular disease.
19. Medical Treatment of Female Sexual Dysfunction, The Urologic Clinics of North America, 2022: A small phase 2 study in postmenopausal women showed modest benefit for bremelanotide, but did not reach the efficacy threshold needed for FDA approval.
20. Novel Pharmacologic Treatments of Female Sexual Dysfunction, Clinical Obstetrics and Gynecology, 2025: Men were studied in early trials for erectile dysfunction, but efficacy was inconsistent and side effects were worse than with PDE5 inhibitors.
21. Pharmacologic therapeutic options for sexual dysfunction, Current Opinion in Obstetrics & Gynecology, 2022: A subgroup analysis suggested bremelanotide might work in women on SSRIs, but the data are preliminary.
22. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent, Drug and Therapeutics Bulletin, 2021: DTB (UK) concluded that the size of the treatment effect is small and of uncertain clinical relevance, recommending bremelanotide should not be used routinely; noted high cost (~$1,000/month in U.S.) and lack of long-term safety data beyond 24 weeks.
23. Polymorphism of Melanocortin Receptor Genes - Association with Inflammatory Traits and Diseases, Diseases, 2025: Some women have polymorphisms in MC4R or MC3R that might predict response to bremelanotide; no genotype-stratified trials have been done.